<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974493</url>
  </required_header>
  <id_info>
    <org_study_id>OVIVA</org_study_id>
    <nct_id>NCT00974493</nct_id>
  </id_info>
  <brief_title>Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&amp;J)</brief_title>
  <acronym>OVIVA</acronym>
  <official_title>Randomized Open Label Study of Oral Versus Intravenous Antibiotic Treatment for Bone and Joint Infections Requiring Prolonged Antibiotic Treatment: Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxford University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the outcomes of treating bone and joint infections with 6 weeks of
      intravenous antibiotics with 6 weeks of oral antibiotic treatment. The trial is of antibiotic
      &quot;strategy&quot; rather than of individual antibiotics. The study will be open label, but the
      primary outcome will be proven failure of infection treatment, determined by pre-established
      objective criteria for treatment failure. The null hypothesis tested is that there will be no
      difference in treatment failure rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A long course of antibiotic therapy given by a &quot;drip&quot; (i.e. intravenous) is recommended
      treatment for many serious bacterial infections. It is costly and inconvenient for the
      patient to remain hospitalised for therapy, so outpatient antibiotic therapy (OPAT)
      programmes have been established in many countries to deliver intravenous antibiotics safely
      and conveniently. The majority of patients referred to OPAT programmes have bone and joint
      infections. However, there is no clear evidence that bone and joint infection really require
      long courses of intravenous antibiotics rather than oral antibiotics.

      We will compare the outcome of treatment with intravenous versus oral antibiotic therapy for
      patients with bone and joint infection. The choice of antibiotic is complex, and antibiotics
      that are suitable oral choices are often not suitable intravenous choices and vice versa.
      Subjects will therefore be randomized to an oral or intravenous &quot;strategy,&quot; rather than to
      individual antibiotics. Outcomes will be determined by pre-established objective criteria for
      treatment failure.

      We have conducted a pilot study in one centre (Oxford), recruiting approximately 200
      patients, and are now expanding to include multi-centre recruitment in the UK, aiming to
      recruit 1050 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Frequency of Definite Failure of Infection Treatment.</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with definite failure of infection treatment defined by microbiological, histological and clinical criteria and assessed by an independent blinded endpoint committee</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1054</enrollment>
  <condition>Bone Infection</condition>
  <condition>Joint Infection</condition>
  <arm_group>
    <arm_group_label>Oral antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
    <arm_group_label>Intravenous antibiotics</arm_group_label>
    <arm_group_label>Oral antibiotics</arm_group_label>
    <other_name>Individual antibiotics not specified by protocol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is willing and able to give informed consent for participation in the study. Has a
             bone and joint infection one of the following categories;

               1. Native osteomyelitis.

               2. Native joint septic arthritis.

               3. Diabetic foot infection with osteomyelitis.

               4. Prosthetic joint associated infection.

               5. Discitis/ spinal osteomyelitis/ epidural abscess

          -  Has had at least 48 hours, but not more than 7 days, of IV antibiotic therapy already
             given after definitive surgical management.

          -  Has a clinical diagnosis of bacterial infection (caused by any organism excepting
             mycobacteria).

          -  Is clinically stable in the opinion of the study clinicians, has no further
             interventions to treat acute infection required or planned.

        Exclusion Criteria:

          -  Has Staph aureus bacteraemia.

          -  Has suspected bacterial endocarditis.

          -  Has suspected mediastinal infection.

          -  Has suspected central nervous system infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Bejon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Radcliffe Hospitals Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Scarborough, MB BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <results_first_submitted>February 24, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxford University Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Matthew Scarborough</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>oral</keyword>
  <keyword>intravenous</keyword>
  <keyword>antibiotics</keyword>
  <keyword>bone</keyword>
  <keyword>joint</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="527"/>
                <participants group_id="P2" count="527"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="509"/>
                <participants group_id="P2" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="527"/>
            <count group_id="B2" value="527"/>
            <count group_id="B3" value="1054"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="527"/>
                    <count group_id="B2" value="527"/>
                    <count group_id="B3" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="18" upper_limit="91"/>
                    <measurement group_id="B2" value="61" lower_limit="18" upper_limit="92"/>
                    <measurement group_id="B3" value="60" lower_limit="18" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="527"/>
                    <count group_id="B2" value="527"/>
                    <count group_id="B3" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="527"/>
                    <count group_id="B2" value="527"/>
                    <count group_id="B3" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="527"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="1054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Frequency of Definite Failure of Infection Treatment.</title>
        <description>Number of participants with definite failure of infection treatment defined by microbiological, histological and clinical criteria and assessed by an independent blinded endpoint committee</description>
        <time_frame>1 year</time_frame>
        <population>Modified ITT (excluding participants without available endpoint data)</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotics</title>
            <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Antibiotics</title>
            <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Definite Failure of Infection Treatment.</title>
          <description>Number of participants with definite failure of infection treatment defined by microbiological, histological and clinical criteria and assessed by an independent blinded endpoint committee</description>
          <population>Modified ITT (excluding participants without available endpoint data)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Antibiotics</title>
          <description>Antibiotics: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All</sub_title>
                <description>Adverse Event data were not available for 8 participants in relation to C difficile and Line Complication. For events collected by non-systematic methods, data are reported with reference to organ system rather than specific adverse event term</description>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>C difficile</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>C difficile was reported as a defined secondary outcome. No data available from 4 participants in each arm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Line complication</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Line complications were reported as a defined secondary outcome. No data available from 4 participants in each arm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplastic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and soft tissue unrelated to original surgical site</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Related to the operative site</sub_title>
                <description>Includes directed specialist care for symptom control, wound management, mobility, skin and soft tissue infection, dislocation or recurrent primary endpoint</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Antibiotic related</sub_title>
                <description>Antibiotic related events represented here were attributed by the responsible infection specialist to antibiotic therapy (as opposed to unrelated co-morbidities).</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Frailty related</sub_title>
                <description>Frailty related events included slips, trips or falls in the elderly or readmission as a result of inability to cope at home</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="527"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Scarborough</name_or_title>
      <organization>Oxford University Hospitals NHS Trust</organization>
      <phone>07872436461</phone>
      <email>matthew.scarborough@ouh.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

